Azenosertib + Carboplatin + Pembrolizumab
Phase 1/2Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple, HER2-negative Breast Cancer
Trial Timeline
May 1, 2024 → Sep 1, 2029
NCT ID
NCT06351332About Azenosertib + Carboplatin + Pembrolizumab
Azenosertib + Carboplatin + Pembrolizumab is a phase 1/2 stage product being developed by Zentalis Pharmaceuticals for Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06351332. Target conditions include Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06351332 | Phase 1/2 | Active |
Competing Products
20 competing products in Breast Cancer